PD176252 is primarily used in research settings as a potent and selective inhibitor of the fibroblast growth factor receptor (FGFR) family. It is particularly valuable in studying the role of FGFR signaling pathways in various biological processes, including cell proliferation, differentiation, and survival. Researchers utilize PD176252 to investigate its potential therapeutic effects in diseases where FGFR signaling is dysregulated, such as certain cancers. By inhibiting FGFR activity, it helps in understanding the molecular mechanisms underlying tumor growth and progression, aiding in the development of targeted cancer therapies. Additionally, it is employed in preclinical studies to explore its efficacy in inhibiting angiogenesis, which is crucial for tumor development and metastasis.